SCHEMBL4989891

SCHEMBL4989891

COCC(N)c1ccc(O)c(O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 11/20 0.50
KDM4E B2RXH2 9/20 0.50
MAPT P10636 9/20 0.50
RECQL P46063 7/20 0.50
LMNA P02545 5/20 0.50
BLM P54132 5/20 0.50
KMT2A Q03164 5/20 0.50
APEX1 P27695 4/20 0.50
MTOR P42345 4/20 0.50
TSHR P16473 3/20 0.50
HIF1A Q16665 3/20 0.50
HSD17B10 Q99714 3/20 0.50
NFKB1 P19838 2/20 0.50
ALOX15 P16050 1/20 0.50
THPO P40225 1/20 0.50
POLB P06746 1/20 0.50
MAPK1 P28482 4/20 0.49
ADRB2 P07550 5/20 0.47
MEN1 O00255 4/20 0.47
ADRA1A P35348 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8667494 0.79 ESR1 (0.43) TDP1KDM4EMAPTLMNABLM
SCHEMBL14303527 0.79 TDP1 (0.62) TDP1KDM4EMAPTRECQLLMNA
SCHEMBL11430514 0.79 TDP1 (0.62) TDP1KDM4EMAPTRECQLLMNA
SCHEMBL8470594 0.79 ESR1 (0.43) TDP1KDM4EMAPTLMNABLM
SCHEMBL13479446 0.79 TDP1 (0.62) TDP1KDM4EMAPTRECQLLMNA
Hydrochloric Acid SCHEMBL17220823 0.77 ALOX15 (0.44) TDP1KDM4EMAPTLMNAAPEX1
SCHEMBL7845490 0.76 TDP1 (0.53) TDP1KDM4EMAPTRECQLLMNA
SCHEMBL11422792 0.76 TDP1 (0.54) TDP1KDM4EMAPTRECQLLMNA
SCHEMBL5050817 0.75 MAPT (0.49) TDP1KDM4EMAPTRECQLLMNA
SCHEMBL12498003 0.74 SLC6A2 (0.50) LMNAHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080139664-A1 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2008-06-12 US claimed
US-20050043408-A1 Anti-glycation agents for preventing age- diabetes- and smoking-related complications NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2005-02-24 US claimed
EP-1435930-A2 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2004-07-14 EP claimed
WO-2003032969-A2 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2003-04-24 WO claimed
US-20080139664-A1 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2008-06-12 US disclosed
US-20050043408-A1 Anti-glycation agents for preventing age- diabetes- and smoking-related complications NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043408-A1 Anti-glycation agents for preventing age- diabetes- and smoking-related complications AGER, GID4, GALE TDP1 1731/4885KDM4E 1767/4885MAPT 1352/4885
US-20080139664-A1 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS AGER, GID4, GALE TDP1 1717/4885KDM4E 1615/4885MAPT 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.